Le Lézard
Classified in: Health
Subject: TRI

VentureMed Completes Enrollment of FLEX Vessel PrepTM System Randomized Control Trial in Arteriovenous Fistulas

MINNEAPOLIS, May 24, 2022 /PRNewswire/ -- VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced today that it has completed enrollment of a randomized clinical trial (RCT) titled "FLEX Vessel Prep Prior To PTA for the Treatment of Obstructive Lesions in the Native AVF". This RCT was conducted to assess primary patency at 6 months when using FLEX Vessel Prep System prior to PTA vs. PTA alone for the treatment of obstructive lesions of native arteriovenous fistulae in the upper extremity. Dialysis patients average 1.9 interventions per year to maintain access and continue lifesaving hemodialysis treatment. Opportunities for better outcomes and to extent the time between interventions are good for patients and save money for healthcare systems.

The FLEX RCT study was a prospective, multi-center, randomized study conducted in 7 sites across the United States. Seventy-five patients were enrolled and includes 30-day, 3 month and 6-month follow-up.

"Although fistula are the preferred access for hemodialysis, fistula dysfunction and failure remains a significant issue in AV dialysis access care. Balloon angioplasty considered the gold standard by most, still has its limitations due to the resistant and recurrent nature of these hyperplasic lesions, often requiring the use of high-pressure balloons," said Sanford Altman, MD, Open Access Vascular Access in Miami Florida. "These high-pressure balloon treatments can cause vessel wall damage accelerating restenosis and shortening the time between interventions. By utilizing the FLEX Vessel Prep prior to angioplasty, we are hoping to see improved vessel compliance, reducing the need for high pressure balloons while reducing the barotrauma to the vessel wall thereby extending the primary patency and time between interventions."

"This RCT builds upon the rich and diverse data we are gathering for the FLEX system. The rapid enrollment of these 75 patients at 7 US centers during a COVID surge is encouraging", said Denis Harrington, president, and chief executive officer of the VentureMed Group. "We are excited to report our previous study, The FLEX AV Registry, will be presented at the VASA 2022 Symposium June 6-9th in Charleston, South Carolina. 2022 is becoming a very impressive year for FLEX Vessel Prep".

About VentureMed Group, Inc. and the FLEX Vessel Prep System
The VentureMed Group, Inc. develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of stenoses of AV fistulas and grafts and PAD. The FLEX VP System is a unique, non-balloon-based approach to optimizing revascularization by creating long controlled-depth micro-incisions that release circumferential tension to improve vessel compliance and enable luminal gain with less vessel trauma that may cause restenosis. FLEX was designed to provide controlled and predictable pre-treatment to optimize outcomes in complex stenoses & lesions of any length or vessel morphology. The FLEX VP System received CE Mark and 510(k) clearance from the US Food and Drug Administration. 

For more information, visit www.VentureMedgroup.com.

Media contact: Kathy Leith
[email protected]

SOURCE VentureMed Group

These press releases may also interest you

at 07:25
The "Biological Control Agents Market - A Global and Regional Analysis: Focus on Product, Application, and Country Analysis - Analysis and Forecast, 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global biological control...

at 07:17
Seniorlink, Inc., the largest provider of...

at 07:13
Elandas, Inc., a SaaS-based configurable technology solutions provider, announced it has merged with long-standing partner AccessSync, LLC, a US-based strategic market access execution services provider. Together, Elandas and AccessSync leadership...

at 07:10
LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, has launched the Rare Mutations and Fusions Lung Cancer Patient Gateway. This new resource joins a suite of Patient Gateways for...

at 07:07
Human Reproduction journal has published the ground-breaking results of an international clinical study, where a novel AI algorithm called Life Whisperer Genetics was developed by AI healthcare company Presegen to assess the genetic integrity of...

at 07:05
XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced it has achieved enrollment of target number of subjects in the Phase 2 portion of its ongoing Phase 1/2...

News published on 24 may 2022 at 13:24 and distributed by: